TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30012192

Group type: COMPARATOR
Intervention: Direct-acting antiviral (DAA) treatment at the local tertiary institution (standard care arm)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Direct-acting antiviral (DAA) treatment at their primary healthcare services (intervention arm)
Number of subjects: 13
Study: 30012324

Group type: EXPERIMENTAL
Intervention: CSF1 (macrophage colony-stimulating factor 1)
Number of subjects: 4147

Group type: EXPERIMENTAL
Intervention: CXCL12 (stromal cell-derived factor 1)
Number of subjects: 4147

Group type: EXPERIMENTAL
Intervention: Other biomarkers (4 well-documented)
Number of subjects: 4147
Study: 30012435

Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir with acid-reducing agents
Number of subjects: 2369

Group type: COMPARATOR
Intervention: Glecaprevir/pibrentasvir without acid-reducing agents
Number of subjects: 2369

Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir with high-dose PPI
Number of subjects: 2369

Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir with low-dose PPI
Number of subjects: 2369
Study: 30012528

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 100 mg 3-weekly, starting 2 weeks before weekly adaptive bladder radiation therapy to a dose of 36 Gy in 6 fractions
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Combination of weekly radiation therapy with pembrolizumab
Number of subjects: 5
Study: 30012546

Group type: EXPERIMENTAL
Intervention: Web-based interface for patients
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Professional users interface
Number of subjects: 169
Study: 30012549

Group type: EXPERIMENTAL
Intervention: Guided social media messages plus the newly developed website (active arm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Website alone (control arm)
Number of subjects: 0
Study: 30012756

Group type: EXPERIMENTAL
Intervention: Murepavadin (novel antipseudomonal antibiotic); single-dose administration; specific dosage not mentioned.
Number of subjects: 0
Study: 30012767

Group type: EXPERIMENTAL
Intervention: Levofloxacin at doses of 11, 14, 17, or 20 mg/kg/day (minimum, 750 mg)
Number of subjects: 101
Study: 30012780

Group type: EXPERIMENTAL
Intervention: Digital Action Research Arm Test assessment
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Enhanced Bi-Manu-Trainer system training for 30 patients
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Action observation and motor imagery tasks
Number of subjects: 75
Study: 30012784

Group type: EXPERIMENTAL
Intervention: Phantom motor execution (PME)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Phantom motor imagery (PMI)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: PME
Number of subjects: 67

Group type: COMPARATOR
Intervention: PMI
Number of subjects: 67
Study: 30012788

Group type: EXPERIMENTAL
Intervention: m-RESIST solution (three mHealth tools: an app, wearable, and a web-based platform)
Number of subjects: 45
Study: 30012817

Group type: EXPERIMENTAL
Intervention: Quantitative magnetic resonance angiography screening and submaximal angioplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: No screening strategy with standard medical management alone
Number of subjects: 0
Study: 30012825

Group type: EXPERIMENTAL
Intervention: Direct quantification of plaque burden (PB)
Number of subjects: 1345

Group type: COMPARATOR
Intervention: Conventional angiographic analysis
Number of subjects: 1345

Group type: EXPERIMENTAL
Intervention: Quantitative analyses of PB and annual change in PB (△PB/y)
Number of subjects: 1345

Group type: EXPERIMENTAL
Intervention: Clinical outcomes recorded
Number of subjects: 1345
Study: 30012869

Group type: EXPERIMENTAL
Intervention: Patients with antecedent hypertension
Number of subjects: 324

Group type: COMPARATOR
Intervention: Patients without antecedent hypertension
Number of subjects: 324
Study: 30013321

Group type: EXPERIMENTAL
Intervention: PPX sustained release (SR)
Number of subjects: 119

Group type: COMPARATOR
Intervention: PPX immediate release (IR)
Number of subjects: 119
Study: 30013367

Group type: EXPERIMENTAL
Intervention: VR-CAP (R-CHOP with bortezomib replacing vincristine)
Number of subjects: 121

Group type: COMPARATOR
Intervention: R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 121
Study: 30013511

Group type: EXPERIMENTAL
Intervention: E2 levels between 14.0 and 17.4 pg/ml
Number of subjects: 252

Group type: COMPARATOR
Intervention: E2 levels ≤10.5 pg/ml
Number of subjects: 252

Group type: COMPARATOR
Intervention: E2 levels 10.6-13.9 pg/ml
Number of subjects: 252

Group type: COMPARATOR
Intervention: E2 levels ≥17.5 pg/ml
Number of subjects: 252
Study: 30013816

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine Dimesylate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30013815

Group type: EXPERIMENTAL
Intervention: Phentermine-Topiramate Extended Release, dosage and duration not available
Number of subjects: 0
Study: 30013821

Group type: EXPERIMENTAL
Intervention: Telephone nutrition health coaching intervention
Number of subjects: 27

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 27
Study: 30013919

Group type: EXPERIMENTAL
Intervention: Gaussian Mixture Model (GMM)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Diffusion Tensor Imaging (DTI)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Neurite Orientation Dispersion and Density Imaging (NODDI)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control (TDC)
Number of subjects: 35
Study: 30015290

Group type: EXPERIMENTAL
Intervention: Galactomannan (GM) in bronchoalveolar lavage (BAL)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Aspergillus specific nested polymerase chain reaction (PCR) in BAL
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional culture in serum
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 1-3-beta-D-glucan (BDG) in BAL
Number of subjects: 44

Group type: COMPARATOR
Intervention: 1-3-beta-D-glucan (BDG) in serum
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Combination of GM and PCR (BAL) with BDG (serum)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Mean GM levels in hematological patients
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: BDG and PCR
Number of subjects: 44
Study: 30016313

Group type: EXPERIMENTAL
Intervention: PCBS (partial correlation based score statistic) method for conditional analysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing methods for imputing missing summary association statistics
Number of subjects: 0
Study: 30016392

Group type: EXPERIMENTAL
Intervention: Vistusertib (50 mg bd for 3/7 days) in combination with weekly paclitaxel (80 mg/m2 for 6/7 weeks) in HGSOC
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Vistusertib (25 mg bd after dose reduction) in combination with weekly paclitaxel (80 mg/m2 for 6/7 weeks) in sqNSCLC
Number of subjects: 87
Study: 30016415

Group type: EXPERIMENTAL
Intervention: Low pulse pressure amplification (L-PPA)
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Systolic BP (SBP) <130 mm Hg (L-SBP)
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Changes in SBP between supine and upright position (O-SBP)
Number of subjects: 883
Study: 30016929

Group type: EXPERIMENTAL
Intervention: Low-molecular weight heparin (LMWH)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Combined therapy (LMWH and low-dose aspirin)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Emergency Caesarean section
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Prospective cohort (only one minor bleeding event reported)
Number of subjects: 264

Group type: COMPARATOR
Intervention: Retrospective cohort
Number of subjects: 264

Group type: COMPARATOR
Intervention: Prospective cohort
Number of subjects: 264
Study: 30016944

Group type: EXPERIMENTAL
Intervention: Collaborative self-management services to promote physical activity (PA)
Number of subjects: 7500000
Study: 30016956

Group type: EXPERIMENTAL
Intervention: DTO™ hybrid dynamic device
Number of subjects: 55
Study: 30016989

Group type: EXPERIMENTAL
Intervention: Bland embolization
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Lipiodol chemoembolization
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Drug-eluting microsphere chemoembolization
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Overall progression-free survival
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Duration of symptom control
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Rate of adverse events
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Interval between embolotherapy cycles
Number of subjects: 180
Study: 30017128

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 30017814

Group type: EXPERIMENTAL
Intervention: Sedation protocol from the RESTORE trial
Number of subjects: 500

Group type: COMPARATOR
Intervention: Matched, healthy siblings of RESTORE patients (unexposed group)
Number of subjects: 500
Study: 30017884

Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg once daily as first-line treatment
Number of subjects: 188
Study: 30017964

Group type: EXPERIMENTAL
Intervention: Visual estimation
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Image fusion
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Transperineal template prostate mapping biopsy
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Multiparametric magnetic resonance imaging targeted biopsies
Number of subjects: 249
Study: 30018092

Group type: EXPERIMENTAL
Intervention: Non-pharmacological intervention to measure acceptance of deprescribing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evaluation of barriers and facilitators of deprescribing perceived by older adults
Number of subjects: 0
Study: 30018133

Group type: EXPERIMENTAL
Intervention: Dasatinib
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Overall response
Number of subjects: 13
Study: 30018134

Group type: EXPERIMENTAL
Intervention: Fixed-dose subcutaneous trastuzumab (H SC) 600 mg every 3 weeks for 18 cycles
Number of subjects: 2573
Study: 30018558

Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS), details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (Control group), details on dosage and duration not available.
Number of subjects: 0
Study: 30018776

Group type: EXPERIMENTAL
Intervention: Echocardiography-derived diastolic dysfunction
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Septal E/e' ratio
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Localised LE
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: ROC curve analysis for septal E/e'
Number of subjects: 146
Study: 30018799

Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg two times per day
Number of subjects: 1578

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1578
Study: 30018811

Group type: EXPERIMENTAL
Intervention: TrasGEX (12-720 mg, intravenously every 3 weeks)
Number of subjects: 37
Study: 30018814

Group type: EXPERIMENTAL
Intervention: FOLFOXIRI plus panitumumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: mFOLFOX6 plus panitumumab
Number of subjects: 0
Study: 30018815

Group type: EXPERIMENTAL
Intervention: Alectinib
Number of subjects: 0
Study: 30019124

Group type: EXPERIMENTAL
Intervention: Comprehensive Primary Care (CPC) initiative
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Matched comparison practices
Number of subjects: 1000
Study: 30019422

Group type: EXPERIMENTAL
Intervention: Post-Stroke Depression toolkit during implementation phase
Number of subjects: 775

Group type: EXPERIMENTAL
Intervention: Post-Stroke Depression toolkit during sustainability phase
Number of subjects: 775

Group type: EXPERIMENTAL
Intervention: Post-Stroke Depression toolkit
Number of subjects: 775
Study: 30021470

Group type: EXPERIMENTAL
Intervention: Intervention group (woman-focused risk-reduction intervention)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 30021547

Group type: EXPERIMENTAL
Intervention: Safe Childbirth Checklist (SCC) implementation with coaching
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health worker questionnaire administered at introduction and 6 months later
Number of subjects: 0
Study: 30021548

Group type: EXPERIMENTAL
Intervention: GOGO (nab-p/gem)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: SLOWGO (gem mono)
Number of subjects: 135

Group type: COMPARATOR
Intervention: FRAIL (best supportive care)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: CGA scores during the course of therapy (CGA1-4)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Response rates
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Safety
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Survival rates
Number of subjects: 135
Study: 30021553

Group type: EXPERIMENTAL
Intervention: Risk assessment model for chronic ankle instability (CAI) based on radiographic and patient characteristics.
Number of subjects: 2370

Group type: EXPERIMENTAL
Intervention: Follow-up questionnaires including the Foot and Ankle Outcome Score and the Cumberland Ankle Instability Tool.
Number of subjects: 2370

Group type: EXPERIMENTAL
Intervention: Radiographic assessment of eleven variables for inter- and intra-observer reliability.
Number of subjects: 2370
Study: 30021552

Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation
Number of subjects: 246
Study: 30021596

Group type: EXPERIMENTAL
Intervention: Kinematic analyses of a drinking task at 3, 6, and 12 months post-stroke
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Stroke Impact Scale-Hand domain evaluation at 12 months post-stroke
Number of subjects: 42

Group type: COMPARATOR
Intervention: Kinematic performance comparison between patients and healthy controls
Number of subjects: 42
Study: 30021705

Group type: EXPERIMENTAL
Intervention: Digital food record using a mobile device (iPod Touch) and FitNinja app for 3 days
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Digital food record
Number of subjects: 17
Study: 30021706

Group type: EXPERIMENTAL
Intervention: Mobile phone-enabled app for providing HIV patients with laboratory test results.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mobile phone-enabled app for improving linkage to HIV care after diagnosis.
Number of subjects: 0
Study: 30021712

Group type: EXPERIMENTAL
Intervention: Family Check-Up Online-only
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Family Check-Up Online + Coach
Number of subjects: 300

Group type: COMPARATOR
Intervention: Waitlist control condition (middle school as usual)
Number of subjects: 300
Study: 30021714

Group type: EXPERIMENTAL
Intervention: Substance Abuse Research Assistant (SARA) mobile application with engagement strategies including push notifications and rewards.
Number of subjects: 73
Study: 30021845

Group type: EXPERIMENTAL
Intervention: Nuclear magnetic resonance-derived measures of LDL-P
Number of subjects: 27888

Group type: COMPARATOR
Intervention: Standard lipid concentrations
Number of subjects: 27888

Group type: EXPERIMENTAL
Intervention: Multivariable-adjusted models comparing extreme tertiles for elevated total LDL-P
Number of subjects: 27888
Study: 30022325

Group type: EXPERIMENTAL
Intervention: Smartphone-recorded sound analysis in the derivation cohort (n=32)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Automated acoustic analysis in the validation cohort (n=59)
Number of subjects: 91
Study: 30023287

Group type: EXPERIMENTAL
Intervention: AA-MF (amino acid medical foods)
Number of subjects: 15

Group type: COMPARATOR
Intervention: GMP-MF (glycomacropeptide medical foods)
Number of subjects: 15
Study: 30023446

Group type: EXPERIMENTAL
Intervention: Gastric bypass (RYGB) and sleeve gastrectomy (SL)
Number of subjects: 55
Study: 30023457

Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 19114
Study: 30024231

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 164
Study: 30024979

Group type: EXPERIMENTAL
Intervention: Postoperative agitation (Sedation-Agitation Scale ≥ 5)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Postoperative agitation
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Bi-frontal pneumocephalus
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Delayed extubation after operation
Number of subjects: 400
Study: 30025081

Group type: EXPERIMENTAL
Intervention: Monocular full-field static perimetry measuring mean sensitivity (MS) and volumetric quantification (in decibel-steradian) for total (VTOT), central 30° (V30), and central 15° (V15) visual field.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Longitudinal analysis of retinal sensitivity.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Volumetric assessment of central 30° visual field sensitivity (V30).
Number of subjects: 19
Study: 30025540

Group type: EXPERIMENTAL
Intervention: Physical Therapy (PT)
Number of subjects: 259

Group type: COMPARATOR
Intervention: Internet-based exercise training (IBET)
Number of subjects: 259
Study: 30026032

Group type: EXPERIMENTAL
Intervention: PCV7
Number of subjects: 3517

Group type: EXPERIMENTAL
Intervention: PCV7 + PCV10
Number of subjects: 3517

Group type: EXPERIMENTAL
Intervention: PCV10
Number of subjects: 3517

Group type: EXPERIMENTAL
Intervention: PCV10 + PCV13
Number of subjects: 3517

Group type: COMPARATOR
Intervention: Unvaccinated
Number of subjects: 3517

Group type: EXPERIMENTAL
Intervention: Overall prevalence of minor abnormalities
Number of subjects: 3517

Group type: EXPERIMENTAL
Intervention: Overall prevalence of major abnormalities
Number of subjects: 3517

Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccination
Number of subjects: 3517

Group type: EXPERIMENTAL
Intervention: Major abnormalities
Number of subjects: 3517
Study: 30026059

Group type: EXPERIMENTAL
Intervention: Apatinib (500 or 750 mg daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Apatinib (after progression)
Number of subjects: 40
Study: 30026110

Group type: EXPERIMENTAL
Intervention: Nilotinib (200 mg/day)
Number of subjects: 37
Study: 30026177

Group type: EXPERIMENTAL
Intervention: Text messaging (SMS) intervention
Number of subjects: 132
Study: 30026275

Group type: EXPERIMENTAL
Intervention: Liraglutide (GLP-1 agonist), dosage and duration not specified
Number of subjects: 0
Study: 30026783

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 675

Group type: COMPARATOR
Intervention: Peritoneal dialysis (PD)
Number of subjects: 675
Study: 30026784

Group type: EXPERIMENTAL
Intervention: Hypocaloric nutritional intervention for 6 months
Number of subjects: 33
Study: 30026785

Group type: EXPERIMENTAL
Intervention: Extra virgin olive oil intake
Number of subjects: 149
Study: 30026787

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (SSC)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 108
Study: 30026911

Group type: EXPERIMENTAL
Intervention: Multi-platform information and communication technology intervention for neonatal resuscitation training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard training for neonatal resuscitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multi-platform information and communication technology intervention for neonatal resuscitation training; details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard training for neonatal resuscitation; details on dosage and duration not available.
Number of subjects: 0
Study: 30026938

Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: No thoracic epidural analgesia
Number of subjects: 0
Study: 30027002

Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg chewable tablets
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 30027104

Group type: EXPERIMENTAL
Intervention: Cladribine tablets 3.5 mg/kg/IFN-β
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo/IFN-β
Number of subjects: 172
Study: 30027121

Group type: EXPERIMENTAL
Intervention: App-based home exercise program using PT PAL, 3 times a week for 6 months
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: App-based home exercise program using PT PAL
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Technology support such as text reminders
Number of subjects: 21
Study: 30027478

Group type: EXPERIMENTAL
Intervention: Azilsartan 5 mg (for patients <50 kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Azilsartan 10 mg (for patients ≥50 kg)
Number of subjects: 6
Study: 30027668

Group type: EXPERIMENTAL
Intervention: Migration (changes of residence over geopolitical boundaries)
Number of subjects: 1919

Group type: EXPERIMENTAL
Intervention: Labour-related mobility
Number of subjects: 1919

Group type: EXPERIMENTAL
Intervention: Non-labour-related mobility
Number of subjects: 1919
Study: 30027687

Group type: EXPERIMENTAL
Intervention: HIV testing services
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Health service interactions
Number of subjects: 148
Study: 30027782

Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum in the head-up position
Number of subjects: 28

Group type: COMPARATOR
Intervention: Baseline measurement
Number of subjects: 28
Study: 30028037

Group type: EXPERIMENTAL
Intervention: Sorafenib combined with 5-azacytidine (AZA)
Number of subjects: 27
Study: 30028985

Group type: EXPERIMENTAL
Intervention: NIR intraoperative imaging using TumorGlow (high-dose indocyanine green and delayed imaging)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NIR intraoperative imaging using TumorGlow
Number of subjects: 20
Study: 30029627

Group type: EXPERIMENTAL
Intervention: COGNITUS & MOI program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Motor skill and video viewing intervention
Number of subjects: 0
Study: 30029674

Group type: EXPERIMENTAL
Intervention: Intraepithelial lymphocytes (IELs) from patients with UC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraepithelial lymphocytes (IELs) from patients with CD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraepithelial lymphocytes (IELs) from patients with CD and axSpA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraepithelial lymphocytes (IELs) from patients with axSpA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraepithelial lymphocytes (IELs) from all disease subtypes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0